絞り込み

16546

広告

1033件中 161件~180件表示    検索結果をPubMedで見る PubMedで見る

Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation.

Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis.

Afatinib in advanced NSCLC: a profile of its use.

Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.

Successful Resection of G719X-Positive Pleomorphic Carcinoma after Afatinib Treatment.

Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.

Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer.

Ligand-Based Pharmacophore Screening Strategy: a Pragmatic Approach for Targeting HER Proteins.

Skin Rash Can Be a Useful Marker for Afatinib Efficacy.

[Patient with Three EGFR Mutations - Gradual Development of Resistance to Previous Targeted Treatment].

Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.

Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.

P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats.

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

Overview of current systemic management of EGFR-mutant NSCLC.

Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.

Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?

The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations.

Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer.

  1. 5
  2. 6
  3. 7
  4. 8
  5. 9
  6. 10
  7. 11
  8. 12
  9. 13
  10. 14
Sort by
※並べ替えは表示に時間がかかります